Cochrane · systematic review · CD010463
Chemotherapy for advanced non‐small cell lung cancer in the elderly population
Santos, FN, de Castria, TB, Cruz, MRS, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
Lung CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
16
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 12.5%Very low 2 · 12.5%Low 9 · 56.3%Moderate 3 · 18.8%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Non‐platinum single‐agent versus non‐platinum combination treatment for non‐small cell lung cancer in the elderly population
Population: non‐small cell lung cancer in the elderly population
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (OS) Non‐platinum single‐agent vs non‐platinum combination treatment | HR 0.92 | 5 studies · 1294 participants | Low Downgraded: risk of bias |
1‐Year survival rate (OS1y) Non‐platinum single‐agent vs non‐platinum combination treatment | RR 0.88 | 4 studies · 993 participants | Low Downgraded: risk of bias |
Progression‐free survival Non‐platinum single‐agent vs non‐platinum combination treatment | HR 0.94 | 4 studies · 1105 participants | Low Downgraded: risk of bias |
Objective response rate (ORR) Non‐platinum single‐agent vs non‐platinum combination treatment | RR 1.79 | 5 studies · 1014 participants | Low Downgraded: risk of bias |
Grade 3 and 4 hematological adverse events (AE) ‐ anemia Non‐platinum single‐agent vs non‐platinum combination treatment | RR 1.18 | 4 studies · 983 participants | Very low Downgraded: risk of bias |
Grade 3 and 4 hematological adverse events (AE) ‐ neutropenia Non‐platinum single‐agent vs non‐platinum combination treatment | RR 1.19 | 5 studies · 1064 participants | Low Downgraded: risk of bias |
Grade 3 and 4 hematological adverse events (AE) ‐ thrombocytopenia Non‐platinum single‐agent vs non‐platinum combination treatment | RR 1.58 | 4 studies · 995 participants | Very low Downgraded: risk of bias |
Quality of life (QoL) Non‐platinum single‐agent vs non‐platinum combination treatment | no estimate extracted | 2 studies · 2 participants | Ungraded |
Non‐platinum therapies compared with platinum combination for non‐small cell lung cancer in the elderly population
Population: non‐small cell lung cancer in the elderly population
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Non‐platinum therapies vs platinum combination | HR 0.76 | 13 studies · 13 participants | Moderate Downgraded: risk of bias |
1‐Year survival rate Non‐platinum therapies vs platinum combination | RR 0.89 | 13 studies · 813 participants | Moderate Downgraded: risk of bias |
Progression‐free survival Non‐platinum therapies vs platinum combination | HR 0.76 | 9 studies · 9 participants | Low Downgraded: risk of bias |
Objective response rate (ORR) Non‐platinum therapies vs platinum combination | RR 1.57 | 11 studies · 1432 participants | Moderate Downgraded: risk of bias |
Grade 3 or higher hematological toxicity for platinum therapies ‐ anemia Non‐platinum therapies vs platinum combination | RR 2.53 | 11 studies · 1437 participants | Low Downgraded: risk of bias |
Grade 3 or higher hematological toxicity for platinum therapies ‐ thrombocytopenia Non‐platinum therapies vs platinum combination | RR 3.59 | 9 studies · 1260 participants | Low Downgraded: risk of bias |
Grade 3 or higher Non‐Hematological Toxicity for Platinum‐based therapies ‐ Peripheral neuropathy Non‐platinum therapies vs platinum combination | RR 7.02 | 5 studies · 776 participants | Low Downgraded: risk of bias |
Quality of life (QoL) Non‐platinum therapies vs platinum combination | no estimate extracted | 5 studies · 5 participants | Ungraded |